These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 16086652)

  • 21. [Drugs used in prophylaxis and treatment of fungal infections in immunosuppressed children].
    Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():89-94. PubMed ID: 15686055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caspofungin: first approved agent in a new class of antifungals.
    Johnson MD; Perfect JR
    Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New antifungal drugs and new clinical trials: interpreting results may be difficult.
    Girmenia C; Martino P
    Curr Opin Oncol; 2003 Jul; 15(4):283-8. PubMed ID: 12874505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caspofungin: a review of its use in the treatment of fungal infections.
    McCormack PL; Perry CM
    Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Micafungin: a therapeutic review.
    Higashiyama Y; Kohno S
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caspofungin: the first representative of a new antifungal class.
    Letscher-Bru V; Herbrecht R
    J Antimicrob Chemother; 2003 Mar; 51(3):513-21. PubMed ID: 12615851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systemic antifungal agents].
    Lumbreras C; Lizasoain M; Aguado JM
    Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options of invasive fungal infections in adults.
    Flückiger U; Marchetti O; Bille J; Eggimann P; Zimmerli S; Imhof A; Garbino J; Ruef C; Pittet D; Täuber M; Glauser M; Calandra T;
    Swiss Med Wkly; 2006 Jul; 136(29-30):447-63. PubMed ID: 16937323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in antifungal therapy.
    Pannaraj PS; Walsh TJ; Baker CJ
    Pediatr Infect Dis J; 2005 Oct; 24(10):921-2. PubMed ID: 16220093
    [No Abstract]   [Full Text] [Related]  

  • 31. Caspofungin therapy of neonates with invasive candidiasis.
    Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
    Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive fungal infections: the challenge continues.
    Gullo A
    Drugs; 2009; 69 Suppl 1():65-73. PubMed ID: 19877737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
    Spanakis EK; Aperis G; Mylonakis E
    Clin Infect Dis; 2006 Oct; 43(8):1060-8. PubMed ID: 16983621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal treatment in pediatric patients.
    Zaoutis TE; Benjamin DK; Steinbach WJ
    Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anidulafungin: a new echinocandin for the treatment of fungal infections.
    Cohen-Wolkowiez M; Benjamin DK; Steinbach WJ; Smith PB
    Drugs Today (Barc); 2006 Aug; 42(8):533-44. PubMed ID: 16969430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.
    Koss T; Bagheri B; Zeana C; Romagnoli MF; Grossman ME
    J Am Acad Dermatol; 2002 Jun; 46(6):945-7. PubMed ID: 12063497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Micafungin: the US perspective.
    Zaas AK; Steinbach WJ
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):183-90. PubMed ID: 15918776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
    Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.